Vaximm AG
Developing active anti-angiogenic immunotherapies for cancer
VAXIMM is a privately held, Swiss-based vaccine company that is primarily focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Our initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. VXM01 has shown impressive anti-tumor activity in various animal studies and is currently being evaluated in clinical trials. VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA. Besides VXM01, VAXIMM has a pipeline of complementary candidate vaccines.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
11.03.2022
NEC Acquires VAXIMM’s Neoantigen Vaccine Development Assets (startupticker.ch)
18.05.2020
VAXIMM’s VXM01 shows encouraging results in Phase I/II study with brain cancer patients (startupticker.ch)
13.11.2019
Biotech company VAXIMM brings NEC as strategic partner and investor on board (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Vaximm AG
Developing active anti-angiogenic immunotherapies for cancer
Website:
www.vaximm.com
NEC
Headquarter:
Basel
Foundation Date:
September 2008
Technology:
- Biotech
Sectors:
- Cancer